SELLAS Life Sciences Group Inc (NASDAQ: SLS) announced results from a new preclinical in vitro study for its highly selective CDK9 inhibitor, GFH009, in neuroendocrine prostate cancer (NEPC).
The data shows that GFH009 demonstrated significant anti-tumor effects in the selected cell line at nanomolar concentrations and, in certain samples, complete growth inhibition with no viable cancer cells.
NEPC is an aggressive variant of prostate cancer. In up to 15%-20% of patients treated with hormonal therapies for prostate adenocarcinoma, small-cell prostate cancer may develop in later stages of prostate cancer progression.
Median survival for NEPC patients whose cancer arose from prior prostate adenocarcinoma is estimated at only 5.4 months.
The conversion to NEPC is associated with recurrent genetic lesions, including mutation or deletion of RB1 and TP53 and the overexpression and genomic amplification of MYCN.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.